Shu-Wen Wan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shu-Wen Wan has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Chih-Peng Chang
Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan
3 shared publications - Tzong-Shiann Ho
Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
3 shared publications Hsing-Han Lin
Affiliations Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, SIDSCO Biomedical Co., Ltd. Kaohsiung, Taiwan
2 shared publicationsPo-Chun Chang
Affiliations Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, Leadgene Biomedical, Inc. Tainan, Taiwan
2 shared publicationsSen-Mao Tien
Affiliation Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
2 shared publicationsTzong‐Shiann Ho
Center of Infectious Disease and Signaling Research National Cheng Kung University Tainan Taiwan
2 shared publications
Latest Publications
- 31 January 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (2) , e70822
A Multivalent Dengue Fusion Protein ΔcNS1–cEDIII–ΔnNS3 Confers Cross‐Serotype Protection and Durable Immunity in Mice
Current dengue vaccines remain limited by serotype‐dependent efficacy and interference from preexisting anti‐dengue immunity. We developed a novel multivalent fusion protein vaccine composed of three engineered dengue virus (DENV) components: a C‐terminal truncated nonstructural protein 1 (ΔcNS1) to block NS1‐mediated pathologic effects without harmful cross‐reactivity, a consensus envelope protein domain III (cEDIII) to induce broad neutralizing antibodies, and an N‐terminal truncated NS3 (ΔnNS3) to enhance cellular immune responses. In a murine dengue disease model, three‐dose immunization with ΔcNS1–cEDIII–ΔnNS3 adjuvanted with Alum provides protection against all four DENV serotypes by significantly reducing viremia and prolonged bleeding time, with elicited robust antibody responses, enhanced cytotoxic activity of CD8 + T cells upon NS1/NS3 restimulation, and increased memory B and T cell populations. Notably, CpG oligodeoxynucleotides 1826 (CpG) plus Alum further enhanced immunogenicity, showing higher neutralizing activity, antigen‐specific plasmablast expansion, and enhanced T cell functional activity, which was associated with more consistent improvement in protection‐relevant outcomes compared with Alum alone. Importantly, two‐dose immunization with CpG plus Alum‐adjuvanted fusion protein conferred durable protection against the virulent DENV2 strain TW2015. These findings support this vaccine as a promising subunit candidate that addresses current limitations, offering both cross‐serotype coverage and potential long‐term efficacy.
- 31 January 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (2) , e70822
A Multivalent Dengue Fusion Protein ΔcNS1–cEDIII–ΔnNS3 Confers Cross‐Serotype Protection and Durable Immunity in Mice
Current dengue vaccines remain limited by serotype‐dependent efficacy and interference from preexisting anti‐dengue immunity. We developed a novel multivalent fusion protein vaccine composed of three engineered dengue virus (DENV) components: a C‐terminal truncated nonstructural protein 1 (ΔcNS1) to block NS1‐mediated pathologic effects without harmful cross‐reactivity, a consensus envelope protein domain III (cEDIII) to induce broad neutralizing antibodies, and an N‐terminal truncated NS3 (ΔnNS3) to enhance cellular immune responses. In a murine dengue disease model, three‐dose immunization with ΔcNS1–cEDIII–ΔnNS3 adjuvanted with Alum provides protection against all four DENV serotypes by significantly reducing viremia and prolonged bleeding time, with elicited robust antibody responses, enhanced cytotoxic activity of CD8 + T cells upon NS1/NS3 restimulation, and increased memory B and T cell populations. Notably, CpG oligodeoxynucleotides 1826 (CpG) plus Alum further enhanced immunogenicity, showing higher neutralizing activity, antigen‐specific plasmablast expansion, and enhanced T cell functional activity, which was associated with more consistent improvement in protection‐relevant outcomes compared with Alum alone. Importantly, two‐dose immunization with CpG plus Alum‐adjuvanted fusion protein conferred durable protection against the virulent DENV2 strain TW2015. These findings support this vaccine as a promising subunit candidate that addresses current limitations, offering both cross‐serotype coverage and potential long‐term efficacy.
- Open Access
- 29 April 2022
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 18 (4) , e1010469
Therapeutic efficacy of humanized monoclonal antibodies targeting dengue virus nonstructural protein 1 in the mouse model
Dengue virus (DENV) which infects about 390 million people per year in tropical and subtropical areas manifests various disease symptoms, ranging from fever to life-threatening hemorrhage and even shock. To date, there is still no effective treatment for DENV disease, but only supportive care. DENV nonstructural protein 1 (NS1) has been shown to play a key role in disease pathogenesis. Recent studies have shown that anti-DENV NS1 antibody can provide disease protection by blocking the DENV-induced disruption of endothelial integrity. We previously demonstrated that anti-NS1 monoclonal antibody (mAb) protected mice from all four serotypes of DENV challenge. Here, we generated humanized anti-NS1 mAbs and transferred them to mice after DENV infection. The results showed that DENV-induced prolonged bleeding time and skin hemorrhage were reduced, even several days after DENV challenge. Mechanistic studies showed the ability of humanized anti-NS1 mAbs to inhibit NS1-induced vascular hyperpermeability and to elicit Fcγ-dependent complement-mediated cytolysis as well as antibody-dependent cellular cytotoxicity of cells infected with four serotypes of DENV. These results highlight humanized anti-NS1 mAb as a potential therapeutic agent in DENV infection.
- 29 April 2022
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 18 (4) , e1010469
Open AccessTherapeutic efficacy of humanized monoclonal antibodies targeting dengue virus nonstructural protein 1 in the mouse model
Dengue virus (DENV) which infects about 390 million people per year in tropical and subtropical areas manifests various disease symptoms, ranging from fever to life-threatening hemorrhage and even shock. To date, there is still no effective treatment for DENV disease, but only supportive care. DENV nonstructural protein 1 (NS1) has been shown to play a key role in disease pathogenesis. Recent studies have shown that anti-DENV NS1 antibody can provide disease protection by blocking the DENV-induced disruption of endothelial integrity. We previously demonstrated that anti-NS1 monoclonal antibody (mAb) protected mice from all four serotypes of DENV challenge. Here, we generated humanized anti-NS1 mAbs and transferred them to mice after DENV infection. The results showed that DENV-induced prolonged bleeding time and skin hemorrhage were reduced, even several days after DENV challenge. Mechanistic studies showed the ability of humanized anti-NS1 mAbs to inhibit NS1-induced vascular hyperpermeability and to elicit Fcγ-dependent complement-mediated cytolysis as well as antibody-dependent cellular cytotoxicity of cells infected with four serotypes of DENV. These results highlight humanized anti-NS1 mAb as a potential therapeutic agent in DENV infection.
- 22 September 2021
- Published by Wiley in IUBMB Life
- Vol. 74 (2) , 170-179
Regulation of innate immune signaling pathways by autophagy in dengue virus infection
Autophagy is not only an intracellular recycling degradation system that maintains cellular homeostasis but is also a component of innate immunity that contributes to host defense against viral infection. The viral components as well as viral particles trapped in autophagosomes can be delivered to lysosomes for degradation. Abundant evidence indicates that dengue virus (DENV) has evolved the potent ability to hijack or subvert autophagy process for escaping host immunity and promoting viral replication. Moreover, autophagy is often required to deliver viral components to pattern recognition receptors signaling for interferon (IFN)‐mediated viral elimination. Hence, this review summarizes DENV‐induced autophagy, which exhibits dual effects on proviral activity of promoting replication and antiviral activity to eliminating viral particles.
- 22 September 2021
- Published by Wiley in IUBMB Life
- Vol. 74 (2) , 170-179
Regulation of innate immune signaling pathways by autophagy in dengue virus infection
Autophagy is not only an intracellular recycling degradation system that maintains cellular homeostasis but is also a component of innate immunity that contributes to host defense against viral infection. The viral components as well as viral particles trapped in autophagosomes can be delivered to lysosomes for degradation. Abundant evidence indicates that dengue virus (DENV) has evolved the potent ability to hijack or subvert autophagy process for escaping host immunity and promoting viral replication. Moreover, autophagy is often required to deliver viral components to pattern recognition receptors signaling for interferon (IFN)‐mediated viral elimination. Hence, this review summarizes DENV‐induced autophagy, which exhibits dual effects on proviral activity of promoting replication and antiviral activity to eliminating viral particles.